IM Cannabis (IMCC) Registration Filing summary

Company overview and business model

• Operates as an international medical cannabis provider, focusing on Israel and Germany, leveraging a data-driven approach and global supply chain to serve medical patients and expand brand presence.

• Shifted strategic focus and resources to Germany following partial legalization in April 2024, aiming for significant growth in this rapidly expanding market.

• In Israel, operates licensed pharmacies, online platforms, and home delivery, enhancing direct patient access and market data collection.

• Implemented operational efficiency measures in Israel during 2024–2025, including logistics optimization, cost reduction, and workforce streamlining.

• German operations are anchored by a licensed logistics and EU-GMP production facility, supporting both own and third-party product distribution.

Financial performance and metrics

• Closed a 2025 private placement for 2,050,000 units at C$2.74 per unit, raising gross proceeds of C$5.62 million.

• Closed a 2024 private placement for 742,517 units at C$2.88 per unit, raising gross proceeds of C$2.14 million.

• As of June 30, 2025, pro forma cash position was C$12.63 million, with total capitalization of C$30.77 million after adjustments.

• Outstanding debt includes C$13.32 million in bank loans and C$571,000 in convertible debentures.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling shareholders; will receive proceeds only from warrant exercises.

• Proceeds from exercised warrants will be used for general working capital, debt repayment, and corporate purposes.